Alzheimerʼs β-amyloid peptide is conformationally modified by apolipoprotein E in vitro

Neuroreport ◽  
1996 ◽  
Vol 7 (3) ◽  
pp. 721-725 ◽  
Author(s):  
Claudio Soto ◽  
Adam Golabek ◽  
Thomas Wisniewski ◽  
Eduardo M. Castaño
1997 ◽  
Vol 319 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Stéphanie Delobette ◽  
Alain Privat ◽  
Tangui Maurice

2019 ◽  
Vol 6 (6) ◽  
pp. 190271 ◽  
Author(s):  
Changliang Liu ◽  
Huan Huang ◽  
Lilusi Ma ◽  
Xiaocui Fang ◽  
Chen Wang ◽  
...  

Misfolding and abnormal aggregation of β-amyloid peptide is associated with the onset and progress of Alzheimer's disease (AD). Therefore, modulating β-amyloid aggregation is critical for the treatment of AD. Herein, we studied the regulatory effects and mechanism of graphene quantum dots (GQDs) on 1–42 β-amyloid (Aβ 1–42 ) aggregation. GQDs displayed significant regulatory effects on the aggregation of Aβ 1–42 peptide as detected by thioflavin T (ThT) assay. Then, the changes of confirmations and structures induced by GQDs on the Aβ 1–42 aggregation were monitored by circular dichroism (CD), dynamic light scattering (DLS) and transmission electron microscope (TEM). The in vitro cytotoxicity experiments further demonstrated the feasibility of GQDs on the regulation of Aβ 1–42 aggregation. Meanwhile, the structural changes of a Aβ 1–42 /GQDs mixture in different pH revealed that electrostatic interaction was the major driving force in the co-assembly process of Aβ 1–42 and GQDs. The proposed mechanism of the regulatory effects of GQDs on the Aβ 1–42 aggregation was also deduced reasonably. This work not only demonstrated the potential feasibility of GQDs as therapeutic drug for AD but also clarified the regulatory mechanism of GQDs on the Aβ 1–42 aggregation.


2002 ◽  
Vol 73 (2) ◽  
pp. 758-769 ◽  
Author(s):  
Laurence Lins ◽  
Annick Thomas-Soumarmon ◽  
Thierry Pillot ◽  
Joël Vandekerckhove ◽  
Maryvonne Rosseneu ◽  
...  

2004 ◽  
Vol 1 (4-5) ◽  
pp. 160-167 ◽  
Author(s):  
M. Hasan Mohajeri ◽  
Meret N.M. Gaugler ◽  
Julia Martinez ◽  
Jay Tracy ◽  
Hong Li ◽  
...  

1998 ◽  
Vol 256 (2) ◽  
pp. 73-76 ◽  
Author(s):  
Daniel Paris ◽  
Terrence Town ◽  
Timothy A Parker ◽  
James Humphrey ◽  
Michael Mullan

1999 ◽  
Vol 72 (1) ◽  
pp. 230-237 ◽  
Author(s):  
Thierry Pillot ◽  
Marc Goethals ◽  
Jamilla Najib ◽  
Christine Labeur ◽  
Laurence Lins ◽  
...  

1997 ◽  
Vol 325 (1) ◽  
pp. 169-175 ◽  
Author(s):  
Cristina HAAS ◽  
Pilar CAZORLA ◽  
Carlos DE MIGUEL ◽  
Fernando VALDIVIESO ◽  
Jesús VÁZQUEZ

Apolipoprotein E (apoE), a protein genetically linked to the incidence of Alzheimer's disease, forms SDS-stable complexes in vitro with β-amyloid peptide (Aβ), the primary component of senile plaques. In the present study, we investigated whether apoE was able to bind full-length Aβ precursor protein (APP). Using a maltose-binding-protein–APP fusion protein and human very-low-density lipoprotein (VLDL), we detected an interaction of apoE with APP that was inhibited by Aβ or anti-apoE antibody. Saturation-binding experiments indicated a single binding equilibrium with an apparent 1:1 stoichiometry and a dissociation constant of 15 nM. An interaction was also observed using apoE from cerebrospinal fluid or delipidated VLDL, as well as recombinant apoE. APP·apoE complexes were SDS-stable, and their formation was not inhibited by reducing conditions; however, they were dissociated by SDS under reducing conditions. ApoE·APP complexes formed high-molecular-mass aggregates, and competition experiments suggested that amino acids 14–23 of Aβ are responsible for complex-formation. Finally, no differences were found when studying the interaction of APP with apoE3 or apoE4. Taken together, our results demonstrate that apoE may form stable complexes with the Aβ moiety of APP with characteristics similar to those of complexes formed with isolated Aβ, and suggest the intriguing possibility that apoE–APP interactions may be pathologically relevant in vivo.


Sign in / Sign up

Export Citation Format

Share Document